Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 23
Filter
1.
EuropePMC; 2020.
Preprint in English | EuropePMC | ID: ppcovidwho-315680

ABSTRACT

Background: COVID-19 is spreading rapidly intercity and international despite rigid public health prevention and control measures been taken. Case presentation : In a cluster of infection, six out of seven participants engaged in persistent singing and talking in confined space were later diagnosed COVID-19 patients. One of the cases was asymptomatic with no SARS-CoV-2 nucleic acid detected, but positive for anti-SARS-CoV-2 IgG. None of the household contacts was infected during the following month. Conclusions: This epidemiological evidence revealed that asymptomatic patients transmitted the coronavirus in confined space with relatively high efficiency, suggesting that it is important to provide better ventilation in public buildings to prevent COVID-19 transmission.

2.
EuropePMC; 2021.
Preprint in English | EuropePMC | ID: ppcovidwho-310723

ABSTRACT

Objectives: : To assess the mental status of Chinese teachers during the COVID-19 epidemic, and to provide theoretical evidences for psychological intervention. Methods: : From October 23, 2020 to December 12, 2020, we conducted the online survey. Generalized Anxiety Disorder 7-item Scale (GAD-7) was used to assess anxiety symptoms. Classified and continuous data were reported as numbers, percentages, and Mean ± SD, respectively. Multivariate Logistic regression model was used to analyze the relationship between different factors and anxiety symptoms. Results: : A total of 10302 university teachers participated in this study, 4416 of them (40.0%) showed anxiety symptoms. Female gender ( OR =1.207) and the age of ≥60 years old ( OR =2.004) were associated with anxiety. Being married ( OR =1.319) was the risk factor for anxiety;being neutral ( OR =1.292), or not-support on returning school ( OR =1.620) was common risk factors for anxiety. Conclusions: : About two-fifths of Chinese university teachers reported anxiety symptoms during the COVID-19 epidemic. The government should pay more attention to the mental health of teachers, take timely and appropriate psychological intervention measures, improve the psychological adjustment ability of teachers, and reduce the psychological harm of COVID-19 epidemic to teachers.

3.
Sci Rep ; 11(1): 23874, 2021 12 13.
Article in English | MEDLINE | ID: covidwho-1569277

ABSTRACT

The worsening progress of coronavirus disease 2019 (COVID-19) is attributed to the proinflammatory state, leading to increased mortality. Statin works with its anti-inflammatory effects and may attenuate the worsening of COVID-19. COVID-19 patients were retrospectively enrolled from two academic hospitals in Wuhan, China, from 01/26/2020 to 03/26/2020. Adjusted in-hospital mortality was compared between the statin and the non-statin group by CHD status using multivariable Cox regression model after propensity score matching. Our study included 3133 COVID-19 patients (median age: 62y, female: 49.8%), and 404 (12.9%) received statin. Compared with the non-statin group, the statin group was older, more likely to have comorbidities but with a lower level of inflammatory markers. The Statin group also had a lower adjusted mortality risk (6.44% vs. 10.88%; adjusted hazard ratio [HR] 0.47; 95% CI, 0.29-0.77). Subgroup analysis of CHD patients showed a similar result. Propensity score matching showed an overall 87% (HR, 0.13; 95% CI, 0.05-0.36) lower risk of in-hospital mortality for statin users than nonusers. Such survival benefit of statin was obvious both among CHD and non-CHD patients (HR = 0.30 [0.09-0.98]; HR = 0.23 [0.1-0.49], respectively). Statin use was associated with reduced in-hospital mortality in COVID-19. The benefit of statin was both prominent among CHD and non-CHD patients. These findings may further reemphasize the continuation of statins in patients with CHD during the COVID-19 era.


Subject(s)
COVID-19/drug therapy , Coronary Disease/drug therapy , Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage , Inpatients/statistics & numerical data , Adult , Aged , Aged, 80 and over , COVID-19/mortality , China/epidemiology , Comorbidity , Coronary Disease/mortality , Female , Hospital Mortality/trends , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Male , Middle Aged , Retrospective Studies , Treatment Outcome
4.
Front Med (Lausanne) ; 8: 582764, 2021.
Article in English | MEDLINE | ID: covidwho-1154222

ABSTRACT

Background: The coronavirus disease 2019 (COVID-19) has swept through the world at a tremendous speed, and there is still limited data available on the treatment for COVID-19. The mortality of severely and critically ill COVID-19 patients in the Optical Valley Branch of Tongji Hospital was low. We aimed to analyze the available treatment strategies to reduce mortality. Methods: In this retrospective, single-center study, we included 1,106 COVID-19 patients admitted to the Optical Valley Branch of Tongji Hospital from February 9 to March 9, 2020. Cases were analyzed for demographic and clinical features, laboratory data, and treatment methods. Outcomes were followed up until March 29, 2020. Results: Inflammation-related indices (hs-CRP, ESR, serum ferritin, and procalcitonin) were significantly higher in severe and critically ill patients than those in moderate patients. The levels of cytokines, including IL-6, IL2R, IL-8, and TNF-α, were also higher in the critical patients. Incidence of acute respiratory distress syndrome (ARDS) in the severely and critically ill group was 23.0% (99/431). Sixty-one patients underwent invasive mechanical ventilation. The correlation between SpO2/FiO2 and PaO2/FiO2 was confirmed, and the cut-off value of SpO2/FiO2 related to survival was 134.43. The mortality of patients with low SpO2/FiO2 (<134.43) at intubation was higher than that of patients with high SpO2/FiO2 (>134.43) (72.7 vs. 33.3%). Among critical patients, the application rates of glucocorticoid therapy, continuous renal replacement therapy (CRRT), and anticoagulation treatment reached 55.2% (238/431), 7.2% (31/431), and 37.1% (160/431), respectively. Among the intubated patients, the application rates of glucocorticoid therapy, CRRT, and anticoagulation treatment were respectively 77.0% (47/61), 54.1% (33/61), and 98.4% (60/61). Conclusion: No vaccines or specific antiviral drugs for COVID-19 have been shown to be sufficiently safe and effective to date. Comprehensive treatment including ventilatory support, multiple organ function preservation, glucocorticoid use, renal replacement therapy, anticoagulation, and restrictive fluid management was the main treatment strategy. Early recognition and intervention, multidisciplinary collaboration, multi-organ function support, and personalized treatment might be the key for reducing mortality.

5.
Disaster Med Public Health Prep ; : 1-5, 2020 Oct 26.
Article in English | MEDLINE | ID: covidwho-1084768

ABSTRACT

Based on the public data from the health departments of Tianjin and Shenzhen, we conducted a comparative analysis of the coronavirus disease 2019 (COVID-19) epidemic situation between these 2 cities. The aim of this study was to evaluate the role of public data in epidemic prevention and control of COVID-19, providing a scientific advice for the subsequent mitigation and containment of COVID-19 prevalence.

6.
Cardiovasc Drugs Ther ; 36(1): 113-120, 2022 02.
Article in English | MEDLINE | ID: covidwho-1006434

ABSTRACT

PURPOSE: To determine the association between low molecular weight heparin (LMWH) use and mortality in hospitalized COVID-19 patients. METHODS: We conducted a retrospective study of patients consecutively enrolled from two major academic hospitals exclusively for COVID-19 in Wuhan, China, from January 26, 2020, to March 26, 2020. The primary outcome was adjusted in-hospital mortality in the LMWH group compared with the non-LMWH group using the propensity score. RESULTS: Overall, 525 patients with COVID-19 enrolled with a median age of 64 years (IQR 19), and 49.33% men. Among these, 120 (22.86%) were treated with LMWH. Compared with the non-LMWH group, the LMWH group was more likely to be older and male; had a history of hypertension, diabetes, coronary heart disease (CHD), or stroke; and had more severe COVID-19 parameters such as higher inflammatory cytokines or D-dimer. Compared with non-LMWH group, LMWH group had a higher unadjusted in-hospital mortality rate (21.70% vs. 11.10%; p = 0.004), but a lower adjusted mortality risk (adjusted odds ratio [OR], 0.20; 95% CI, 0.09-0.46). A propensity score-weighting analysis demonstrated similar findings (adjusted OR, 0.18; 95% CI, 0.10-0.30). Subgroup analysis showed a significant survival benefit among those who were severely (adjusted OR, 0.07; 95% CI, 0.02-0.23) and critically ill (adjusted OR, 0.32; 95% CI, 0.15-0.65), as well as among the elderly patients' age > 65, IL-6 > 10 times upper limit level, and D-dimer > 5 times upper limit level. CONCLUSIONS: Among hospitalized COVID-19 patients, LMWH use was associated with lower all-cause in-hospital mortality than non-LMWH users. The survival benefit was particularly significant among more severely ill patients.


Subject(s)
Anticoagulants/therapeutic use , COVID-19/drug therapy , Heparin, Low-Molecular-Weight/therapeutic use , Hospitalization , Aged , Aged, 80 and over , Anticoagulants/adverse effects , Blood Coagulation/drug effects , COVID-19/diagnosis , COVID-19/mortality , China/epidemiology , Comorbidity , Female , Hemorrhage/chemically induced , Heparin, Low-Molecular-Weight/adverse effects , Hospital Mortality , Humans , Male , Middle Aged , Retrospective Studies , Risk Assessment , Risk Factors , Severity of Illness Index , Time Factors , Treatment Outcome
8.
J Am Heart Assoc ; 9(21): e017736, 2020 11 03.
Article in English | MEDLINE | ID: covidwho-901509

ABSTRACT

Background There has been significant controversy regarding the effects of pre-hospitalization use of renin-angiotensin system (RAS) inhibitors on the prognosis of hypertensive COVID-19 patients. Methods and Results We retrospectively assessed 2,297 hospitalized COVID-19 patients at Tongji Hospital in Wuhan, China, from January 10th to March 30th, 2020; and identified 1,182 patients with known hypertension on pre-hospitalization therapy. We compared the baseline characteristics and in-hospital mortality between hypertensive patients taking RAS inhibitors (N=355) versus non-RAS inhibitors (N=827). Of the 1,182 hypertensive patients (median age 68 years, 49.1% male), 12/355 (3.4%) patients died in the RAS inhibitors group vs. 95/827 (11.5%) patients in the non-RAS inhibitors group (p<0.0001). Adjusted hazard ratio for mortality was 0.28 (95% CI 0.15-0.52, p<0.0001) at 45 days in the RAS inhibitors group compared with non-RAS inhibitors group. Similar findings were observed when patients taking angiotensin receptor blockers (N=289) or angiotensin converting enzyme inhibitors (N=66) were separately compared with non-RAS inhibitors group. The RAS inhibitors group compared with non-RAS inhibitors group had lower levels of C-reactive protein (median 13.5 vs. 24.4 pg/mL; p=0.007) and interleukin-6 (median 6.0 vs. 8.5 pg/mL; p=0.026) on admission. The protective effect of RAS inhibitors on mortality was confirmed in a meta-analysis of published data when our data were added to previous studies (odd ratio 0.44, 95% CI 0.29-0.65, p<0.0001). Conclusions In a large single center retrospective analysis we observed a protective effect of pre-hospitalization use of RAS inhibitors on mortality in hypertensive COVID-19 patients; which might be associated with reduced inflammatory response.


Subject(s)
Angiotensin Receptor Antagonists/therapeutic use , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Antihypertensive Agents/therapeutic use , Coronavirus Infections/mortality , Hospital Mortality , Hypertension/drug therapy , Patient Admission , Pneumonia, Viral/mortality , Renin-Angiotensin System/drug effects , Adult , Aged , COVID-19 , China , Coronavirus Infections/diagnosis , Coronavirus Infections/therapy , Female , Humans , Hypertension/diagnosis , Hypertension/mortality , Male , Middle Aged , Pandemics , Pneumonia, Viral/diagnosis , Pneumonia, Viral/therapy , Prognosis , Protective Factors , Retrospective Studies , Risk Assessment , Risk Factors
9.
Int J Cardiol ; 324: 131-138, 2021 02 01.
Article in English | MEDLINE | ID: covidwho-893924

ABSTRACT

Fulminant myocarditis (FM) is a form of acute myocardial inflammation leading to rapid-onset hemodynamic instability due to cardiogenic shock or life-threatening arrhythmias. As highlighted by recent registries, FM is associated with high rates of death and heart transplantation, regardless of the underlying histology. Because of a paucity of evidence-based management strategies exists for this disease, an International workshop on FM was held in Wuhan, China, in October 2019, in order to share knowledge on the disease and identify areas of consensus. The present report highlights both agreements and controversies in FM management across the world, focusing the attention on areas of opportunity, FM definition, the use of endomyocardial biopsy and viral identification on heart specimens, treatment algorithms including immunosuppression and the timing of circulatory support escalation. This report incorporates the most recent recommendations from national and international professional societies. Main areas of interest and aims of future prospective observational registries and randomized controlled trials were finally identified and suggested.


Subject(s)
COVID-19/epidemiology , Disease Management , Education/methods , Internationality , Myocarditis/epidemiology , COVID-19/therapy , China/epidemiology , Education/trends , Heart Failure/epidemiology , Heart Failure/therapy , Humans , Myocarditis/therapy
10.
SSRN; 2020.
Preprint | SSRN | ID: ppcovidwho-1093

ABSTRACT

Background: Overall death cause of COVID-19 patients has been reported but attribution of myocardial injury remains undetermined. br br Methods: We extracted d

11.
SSRN; 2020.
Preprint | SSRN | ID: ppcovidwho-864

ABSTRACT

Coronavirus disease 2019 (COVID-19) has been pandemic and is leading to many deaths due to refractory respiratory failure. Here, we report our experience of tre

12.
SSRN; 2020.
Preprint | SSRN | ID: ppcovidwho-669

ABSTRACT

Background: The risk of acute kidney injury (AKI) in severe and critical COVID-19 patients needs to be defined. br br Methods: A total of 61 severe and critic

14.
J Mol Cell Cardiol ; 147: 74-87, 2020 10.
Article in English | MEDLINE | ID: covidwho-722814

ABSTRACT

BACKGROUND: Cardiac injury, as measured by troponin elevation, has been reported among hospitalized coronavirus disease 2019 (COVID-19) patients and portends a poor prognosis. However, how the dynamics of troponin elevation interplay with inflammation and coagulation biomarkers over time is unknown. We assessed longitudinal follow-up of cardiac injury, inflammation and coagulation markers in relation to disease severity and outcome. METHODS: We retrospectively assessed 2068 patients with laboratory-confirmed COVID-19 between January 29 and April 1, 2020 at Tongji Hospital in Wuhan, China. We defined cardiac injury as an increase in high sensitivity cardiac troponin-I (hs-cTnI) above the 99th of the upper reference limit. We explored the dynamics of elevation in hs-cTnI and the relationship with inflammation (interleukin [IL]-6, IL-8, IL-10, IL-2 receptor, tumor necrosis factor-α, C-reactive protein) and coagulation (d-dimer, fibrinogen, international normalized ratio) markers in non-critically ill versus critically ill patients longitudinally and further correlated these markers to survivors and non-survivors. RESULTS: Median age was 63 years (first to third quartile 51-70 years), 51.4% of whom were women. When compared to non-critically ill patients (N = 1592, 77.0%), critically ill (defined as requiring mechanical ventilation, in shock or multiorgan failure) patients (N = 476, 23.0%), had more frequent cardiac injury on admission (30.3% vs. 2.3%, p < 0.001), with increased mortality during hospitalization (38.4% vs. 0%, p < 0.001). Among critically ill patients, non-survivors (N = 183) had a continuous increase in hs-cTnI levels during hospitalization, while survivors (N = 293) showed a decrease in hs-cTnI level between day 4 and 7 after admission. Specifically, cardiac injury is an independent marker of mortality among critically ill patients at admission, day 4-7 and 8-14. Consistent positive correlations between hs-cTnI and interleukin (IL)-6 on admission (r = 0.59), day 4-7 (r = 0.66) and day 8-14 (r = 0.61; all p < 0.001) and d-dimer (at the same timepoints r = 0.54; 0.65; 0.61, all p < 0.001) were observed. A similar behavior was observed between hs-cTnI and most of other biomarkers of inflammation and coagulation. CONCLUSIONS: Cardiac injury commonly occurs in critically ill COVID-19 patients, with increased levels of hs-cTnI beyond day 3 since admission portending a poor prognosis. A consistent positive correlation of hs-cTnI with IL-6 and d-dimer at several timepoints along hospitalization could suggest nonspecific cytokine-mediated cardiotoxicity.


Subject(s)
Coronavirus Infections/pathology , Cytokines/blood , Heart Injuries/pathology , Pneumonia, Viral/pathology , Troponin I/blood , Aged , Betacoronavirus , Biomarkers/blood , Blood Coagulation/physiology , COVID-19 , Coronavirus Infections/blood , Critical Illness , Female , Heart Injuries/blood , Heart Injuries/diagnosis , Humans , Inflammation , Longitudinal Studies , Male , Middle Aged , Pandemics , Pneumonia, Viral/blood , Prognosis , Retrospective Studies , SARS-CoV-2
15.
Int J Infect Dis ; 99: 84-91, 2020 Oct.
Article in English | MEDLINE | ID: covidwho-692871

ABSTRACT

BACKGROUND: The antiviral effects of Novaferon, a potent antiviral protein drug, on COVID-19 was evaluated in the laboratory, and in a randomized, open-label, parallel-group trial. METHODS: In the laboratory, Novaferon's inhibition of viral replication in cells infected with SARS-CoV-2, and prevention of SARS-CoV-2 entry into healthy cells was determined. Antiviral effects of Novaferon in COVID-19 patients with treatment of Novaferon, Novaferon plus Lopinavir/Ritonavir, or Lopinavir/Ritonavir were evaluated. The primary endpoint was the SARS-CoV-2 clearance rates on day six of treatment, and the secondary endpoint was the time to SARS-CoV-2 clearance. RESULTS: Novaferon inhibited viral replication (EC50=1.02ng/ml), and prevented viral infection (EC50=0.10ng/ml). Results from the 89 enrolled COVID-19 patients showed that both Novaferon and Novaferon plus Lopinavir/Ritonavir groups had significantly higher viral clearance rates on day six than Lopinavir/Ritonavir group (50.0% vs. 24.1%, p=0.0400, and 60.0% vs. 24.1%, p=0.0053). The median time to viral clearance was six days, six days, and nine days for three groups, respectively, a 3-day reduction in both the Novaferon and Novaferon plus Lopinavir/Ritonavir groups compared with the Lopinavir/Ritonavir group. CONCLUSIONS: Novaferon exhibited anti-SARS-CoV-2 effects in vitro and in COVID-19 patients. These data justify further evaluation of Novaferon. TRIAL REGISTRATION NUMBER: Number ChiCTR2000029496 at the Chinese Clinical Trial Registry (http://www.chictr.org.cn/).


Subject(s)
Betacoronavirus/drug effects , Coronavirus Infections/drug therapy , Interferons/therapeutic use , Pneumonia, Viral/drug therapy , Administration, Inhalation , Antiviral Agents/administration & dosage , Antiviral Agents/therapeutic use , COVID-19 , Female , Humans , Interferons/administration & dosage , Male , Pandemics , Recombinant Proteins/administration & dosage , Recombinant Proteins/therapeutic use , SARS-CoV-2 , Virus Replication/drug effects
16.
Sci China Life Sci ; 63(10): 1617-1618, 2020 Oct.
Article in English | MEDLINE | ID: covidwho-625919

ABSTRACT

1. In the abstract, we missed a piece of information. The correct sentence should be "In this retrospective study, we included 550 critically ill COVID-19 patients who need mechanical ventilation (63.5%) and oxygen therapy (35.6%) in Tongji Hospital, Wuhan, from February 1, 2020 to April 4, 2020." 2. We mistakenly put an approval number from Tongji Hospital ethics committee in the paper (IRBID: TJ-C20200113). The correct number should be TJ-IRB20200229. 3. We mistakenly filled some data in Table 1 and the correct Table 1 (the corrected data are in boldface) should be as follows.

17.
Front Public Health ; 8: 267, 2020.
Article in English | MEDLINE | ID: covidwho-615606

ABSTRACT

Asymptomatic individuals with coronavirus disease (COVID-19) have been identified via nucleic acid testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); however, the epidemiologic characteristics and viral shedding pattern of asymptomatic patients remain largely unknown. In this study, serological testing was applied when identifying nine asymptomatic cases of COVID-19 who showed persistent negative RT-PCR test results for SARS-CoV-2 nucleic acid and no symptoms of COVID-19. Two asymptomatic cases were presumed to be index patients who had cleared the virus when their close contacts developed symptoms of COVID-19. Three of the asymptomatic cases were local individuals who spontaneously recovered before their presumed index patients developed symptoms of COVID-19. This report presents the epidemiologic and clinical characteristics of asymptomatic individuals with SARS-CoV-2 infection that were undetected on RT-PCR tests in previous epidemiologic investigations probably due to the transient viral shedding duration.


Subject(s)
Asymptomatic Diseases , COVID-19 Serological Testing , COVID-19 , Reverse Transcriptase Polymerase Chain Reaction , COVID-19/diagnosis , COVID-19/transmission , Female , Humans , Male , Middle Aged , SARS-CoV-2/isolation & purification
18.
Sci China Life Sci ; 63(11): 1678-1687, 2020 11.
Article in English | MEDLINE | ID: covidwho-610883

ABSTRACT

Coronavirus disease 2019 (COVID-19) is a global pandemic which has caused numerous deaths worldwide. The present study investigated the roles of hypoproteinemia in the clinical outcome and liver dysfunction of COVID-19 patients. In this retrospective study, we extracted data from 2,623 clinically confirmed adult COVID-19 patients (>18 years old) between January 29, 2020 and March 6, 2020 in Tongji Hospital, Wuhan, China. The patients were divided into three groups-non-critically ill, critically ill, and death groups-in accordance with the Chinese Clinical Guideline for COVID-19. Serum albumin, low-density lipoproteins cholesterol (LDL-C), and high-density lipoproteins cholesterol (HDL-C) concentrations and inflammatory cytokines levels were measured and compared among these three groups. The median age of these 2,623 patients was 64 years old (interquartile range (IQR), 52-71). Among the patients enrolled in the study, 2,008 (76.6%) were diagnosed as non-critically ill and 615 (23.4%) were critically ill patients, including 383 (14.6%) critically ill survivors and 232 (8.8%) critically ill deaths in the hospital. Marked hypoalbuminemia occurred in 38.2%, 71.2%, and 82.4% patients in non-critically ill, critically ill, and death groups, respectively, on admission and 45.9%, 77.7%, and 95.6% of these three groups, respectively, during hospitalization. We also discovered that serum low-density lipoprotein (LDL) and HDL levels were significantly lower in critically ill and death groups compared to non-critically ill group. Meanwhile, the patients displayed dramatically elevated levels of serum inflammatory factors, while a markedly prolonged activated partial thromboplastin time (APTT) in critically ill patients reflected coagulopathy. This study suggests that COVID-19-induced cytokine storm causes hepatotoxicity and subsequently critical hypoalbuminemia, which are associated with exacerbation of disease-associated inflammatory responses and progression of the disease and ultimately leads to death for some critically ill patients.


Subject(s)
COVID-19/blood , COVID-19/complications , Coronavirus Infections/blood , Coronavirus Infections/complications , Liver Diseases/etiology , Serum Albumin, Human/metabolism , Aged , COVID-19/mortality , China , Cholesterol, HDL/blood , Cholesterol, LDL/blood , Coronavirus Infections/mortality , Critical Illness , Cytokines/blood , Female , Humans , Liver Diseases/blood , Male , Middle Aged , Prognosis , Retrospective Studies , Risk Factors , SARS-CoV-2 , Thromboplastin/metabolism , Time Factors
19.
Brain Behav Immun ; 88: 60-65, 2020 08.
Article in English | MEDLINE | ID: covidwho-549072

ABSTRACT

BACKGROUND: The emergency department is considered to be a high-risk area, as it is often the first stop for febrile patients who are subsequently diagnosed with coronavirus disease 2019. This study, which employed a cross-sectional design, aimed to assess the mental health of emergency department medical staff during the epidemic in China. METHODS: Demographic data and mental health measurements were collected by electronic questionnaires from February 28, 2020 to March 18, 2020. OUTCOMES: A total of 14,825 doctors and nurses in 31 provinces of mainland China completed the survey. The prevalence rates of depressive symptoms and post-traumatic stress disorder (PTSD) were 25.2% and 9.1%, respectively. Men were more likely to have depressive symptoms and PTSD than women. Those who were middle aged, worked for fewer years, had longer daily work time, and had lower levels of social support were at a higher risk of developing depressive symptoms and PTSD. Working in the Hubei province was associated with a higher risk of depressive symptoms, while those working in the Hubei province but residing in another province had a lower risk of depressive symptoms and PTSD. Being a nurse was associated with a higher risk of PTSD. INTERPRETATION: The findings suggest that targeted psychological interventions to promote the mental health of medical staff with psychological problems need to be immediately implemented. Special attention should be paid to local medical staff in Hubei.


Subject(s)
Coronavirus Infections , Depression/epidemiology , Emergency Medicine , Emergency Nursing , Nurses/psychology , Pandemics , Physicians/psychology , Pneumonia, Viral , Stress Disorders, Post-Traumatic/epidemiology , Adult , Age Distribution , Betacoronavirus , COVID-19 , China/epidemiology , Depression/psychology , Emergency Service, Hospital , Female , Humans , Male , Mental Health , Personnel Staffing and Scheduling , Prevalence , SARS-CoV-2 , Sex Distribution , Social Support , Stress Disorders, Post-Traumatic/psychology
SELECTION OF CITATIONS
SEARCH DETAIL